Orthocell Limited announced it has appointed Device Technologies ("DVT") as its exclusive distributor of RemplirTM for peripheral nerve repair across Australia and New Zealand. The distributor agreement follows the Australian market approval for its RemplirTM peripheral nerve repair device received in March 2022 and the Company's application for inclusion of RemplirTM on the Australian Prostheses List. Inclusion on the Prostheses List, if successful, will enable practitioners to receive reimbursement from private insurers for use of RemplirTM in approved peripheral nerve repair procedures, reducing costs to the patient.

Device Technologies will market and distribute RemplirTM for use in the surgical repair of peripheral nerves across Australia and New Zealand, undertaking targeted promotion activities, initiating sales, as well as expanding the network of referring plastic and orthopaedic surgeons. The exclusive distribution agreement has an initial term of five years and enables Orthocell access to this strategic market, with a growing uptake of Australian Made, high-quality healthcare products.